- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00093821
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
A Multicenter Phase I Trial of 17-N-allylamino-17-demethoxy Geldanamycin (17-AAG, NSC #330507) in Patients With Recurrent/Refractory Pediatric Solid Tumors (Ewing's Sarcoma, Desmoplastic Small Round Cell Tumor, Osteosarcoma, Neuroblastoma, and Rhabdomyosarcoma) and Leukemia
Study Overview
Status
Conditions
- Childhood Chronic Myelogenous Leukemia
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Recurrent Neuroblastoma
- Recurrent Osteosarcoma
- Recurrent Childhood Rhabdomyosarcoma
- Metastatic Osteosarcoma
- Disseminated Neuroblastoma
- Previously Treated Childhood Rhabdomyosarcoma
- Recurrent Childhood Soft Tissue Sarcoma
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Metastatic Childhood Soft Tissue Sarcoma
- Childhood Desmoplastic Small Round Cell Tumor
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the dose-limiting toxicity and maximum tolerated dose (MTD) of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) in pediatric patients with recurrent or refractory leukemia or selected solid tumors.
II. Determine the levels of key proteins known to influence cancer cell survival and proliferation in patients treated with this drug at the MTD.
SECONDARY OBJECTIVES:
I. Determine the pharmacokinetics of this drug in these patients. II. Evaluate effects of genetic polymorphisms known to alter the activity of enzymes involved in the metabolism of this drug.
III. Correlate the alteration of fludeoxyglucose F18 accumulation with tumor response in patients treated with this drug.
OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to diagnosis (leukemia vs solid tumor).
Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11 (for patients with solid tumors) OR days 1, 4, 8, 11, 15, and 18 (for patients with leukemia). Courses for all patients repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tanespimycin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 15 patients are treated at the MTD.
Patients are followed for 30 days.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically confirmed diagnosis of 1 of the following malignancies:
Leukemia
- Lymphoid, myeloid, or mixed lineage
Relapsed (in second or greater relapse) or refractory disease, confirmed by 1 of the following:
- Bone marrow relapse, defined as either M3 bone marrow (> 25% blasts in the bone marrow aspirate) OR M2 bone marrow (5-25% blasts in the bone marrow aspirate) at any time after complete remission is attained
- CNS relapse, defined as at least 5 WBC/mL by cytospin of any cerebrospinal fluid (CSF) specimen OR less than 5 WBC/mL by cytospin of 2 consecutive CSF specimens obtained >= 4 weeks apart and having definitive confirmation that blasts are derived from the original leukemic clone by molecular cytogenetics, multiparameter flow cytometry, or immunostaining of >= 2 antigens
- Patients with underlying chronic myeloid leukemia must have > 25% blasts in the bone marrow aspirate
- Patients with M3 bone marrow AND extramedullary sites of disease, other than leptomeningeal disease, are eligible
Solid tumor
One of the following tumor types:
- Neuroblastoma
- Ewing's sarcoma
- Osteosarcoma
- Desmoplastic small round cell tumor
- Rhabdomyosarcoma
- Progressed after prior standard therapy OR no effective standard therapy exists
- Measurable or nonmeasurable disease
- No known brain metastases
No active leptomeningeal leukemia, defined by the following criteria:
- WBC > 5/mm^3 in cerebrospinal fluid (CSF)
- Unequivocal confirmation of leukemic blasts in CSF by cell morphology
- No symptomatic CNS disease (e.g., cranial nerve abnormalities) without cytologic abnormality in CSF
- Performance status - Karnofsky 70-100% (for patients > 10 years of age)
- Performance status - Lansky 70-100% (for patients =< 10 years of age)
- More than 8 weeks
- Absolute neutrophil count >= 750/mm^3
- Platelet count >= 75,000/mm^3 (transfusion independent)
- Hemoglobin >= 8.5 g/dL (transfusion allowed)
- Bilirubin < 1.5 mg/dL
- ALT and AST =< 2.5 times upper limit of normal (ULN)
- INR =< 1.5 times ULN
- Albumin > 2.0 g/dL
- Creatinine =< 1.5 times ULN for age
- Creatinine clearance or radioisotope glomerular filtration rate > 60 mL/min
- Ejection fraction >= 50%
- Shortening fraction >= 28%
QTc < 450 msec for men (470 msec for women)
- No congenital long QT syndrome
- LVEF > 40% by MUGA
- No symptomatic congestive heart failure
- No cardiac arrhythmia
- No New York Heart Association class III or IV heart failure
- No myocardial infarction within the past year
- No uncontrolled dysrhythmias
- No poorly controlled angina
- More than 12 months since active ischemic heart disease
- No history of serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation >= 3 beats in a row)
- No left bundle branch block
- No other significant cardiac disease
- No pulmonary fibrosis by radiography
- No ongoing or active bacterial or fungal infection
- No other uncontrolled illness
- No psychiatric illness or social situation that would preclude study compliance
- No history of serious allergic reaction attributed to eggs or dimethyl sulfoxide
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Recovered from all immunotherapy
- At least 6 months since prior allogeneic stem cell transplantation
- At least 3 months since prior autologous stem cell transplantation
- At least 2 weeks since prior biologic agents (e.g., monoclonal antibodies)
- At least 1 week since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
- Recovered from all prior chemotherapy
- At least 2 weeks since prior chemotherapy (for patients with leukemia only)
- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) (for patients with solid tumors)
- No prior oxaliplatin
- No concurrent corticosteroids except for the treatment of adrenal crises in patients with suppressed hypothalamic-pituitary-adrenal axis response OR for treatment of allergic reactions to medications or blood products
- Recovered from all prior radiotherapy
- At least 6 months since prior radiotherapy to >= 50% of the pelvis
- At least 6 months since prior radiotherapy to substantial bone marrow, including total body irradiation
- At least 4 weeks since prior local (small port) radiotherapy
- No prior radiotherapy to the heart
- At least 1 week since prior retinoids
- No concurrent antiretroviral therapy for HIV-positive patients
- No concurrent medication to control arrhythmias
- No concurrent medications that prolong or may prolong QTc interval
- No other concurrent investigational agents
- No other concurrent anticancer therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment (tanespimycin)
Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11 (for patients with solid tumors) OR days 1, 4, 8, 11, 15, and 18 (for patients with leukemia). Courses for all patients repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 15 patients are treated at the MTD. |
Correlative studies
Correlative studies
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MTD, defined as the highest dose level with an observed incidence of DLT in no more than 1 out of 6 patients treated at a particular dose level
Time Frame: 21 days
|
21 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Hsp90 client protein levels in relation to dose of tanespimycin
Time Frame: Baseline to 21 days
|
Baseline to 21 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tanya Trippett, Memorial Sloan Kettering Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Neoplasms, Neuroepithelial
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Leukemia, Lymphoid
- Neoplasms, Bone Tissue
- Neoplasms, Connective Tissue
- Neoplasms, Muscle Tissue
- Myosarcoma
- Neoplasms
- Sarcoma
- Leukemia
- Leukemia, Myeloid
- Recurrence
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Sarcoma, Ewing
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Osteosarcoma
- Neuroblastoma
- Rhabdomyosarcoma
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors, Primitive, Peripheral
- Rhabdomyosarcoma, Embryonal
- Desmoplastic Small Round Cell Tumor
Other Study ID Numbers
- NCI-2012-01456
- U01CA069856 (U.S. NIH Grant/Contract)
- 04-069
- POETIC-MSKCC-04069
- CDR0000391010
- NCI-6323
- MSKCC-04069
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Childhood Chronic Myelogenous Leukemia
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Accelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedAccelerated Phase Chronic Myelogenous Leukemia | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedChildhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedChildhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedJuvenile Myelomonocytic Leukemia | Childhood Acute Myeloid Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Childhood Chronic Myelogenous Leukemia | Childhood Myelodysplastic Syndromes | Chronic Phase Chronic Myelogenous Leukemia | Previously Treated Myelodysplastic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedAccelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous LeukemiaUnited States
-
Stanford UniversityTerminatedPrimary Myelofibrosis | Myelofibrosis | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Non-Hodgkin Lymphoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Refractory Non-Hodgkin Lymphoma | Blast... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedChildhood Acute Promyelocytic Leukemia (M3) | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Blastic Phase Chronic Myelogenous LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedJuvenile Myelomonocytic Leukemia | Recurrent Disease | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Childhood Solid Neoplasm | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia... and other conditionsUnited States, Canada
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Chronic Myelogenous Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Relapsing Chronic Myelogenous Leukemia and other conditionsUnited States
Clinical Trials on laboratory biomarker analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States